RightFit Trial Directory

Lung Cancer clinical trials in Nashville, TN

66 recruiting lung cancer studies with a site in Nashville, TN.

All trials in Nashville, TN · All Lung Cancer trials

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Memphis, TN · Nashville, TN · +38 more sites

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

Memphis, TN · Nashville, TN · +27 more sites

RecruitingPhase 1NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sponsor: Eli Lilly and Company

Nashville, TN · +21 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Chattanooga, TN · Knoxville, TN · Memphis, TN · +51 more sites

RecruitingPhase 1NCT03460977

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Sponsor: Pfizer

Nashville, TN · +43 more sites

RecruitingPhase 1NCT06545331

Study of XB010 in Subjects With Solid Tumors

Sponsor: Exelixis

Nashville, TN · +15 more sites

RecruitingPhase 2 / Phase 3NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Sponsor: BioNTech SE

Knoxville, TN · Memphis, TN · Nashville, TN · +50 more sites

RecruitingPhase 1 / Phase 2NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sponsor: Verastem, Inc.

Nashville, TN · +12 more sites

RecruitingPhase 1NCT07462377

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Sponsor: EpiBiologics

Nashville, TN · +5 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

Nashville, TN · +20 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Nashville, TN · +19 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Bartlett, TN · Chattanooga, TN · +238 more sites

RecruitingPhase 1NCT07519655

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Sponsor: Pfizer

Nashville, TN · +9 more sites

RecruitingPhase 2 / Phase 3NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Sponsor: Bristol-Myers Squibb

Chattanooga, TN · Nashville, TN · +26 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Chattanooga, TN · Franklin, TN · +223 more sites

RecruitingPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor: Genmab

Nashville, TN · +35 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Chattanooga, TN · Knoxville, TN · Memphis, TN · +84 more sites

RecruitingPhase 2NCT05967689

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Sponsor: Taiho Oncology, Inc.

Nashville, TN · +17 more sites

RecruitingPhase 1 / Phase 2NCT06780137

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Sponsor: Merck Sharp & Dohme LLC

Nashville, TN · +8 more sites

RecruitingPhase 2 / Phase 3NCT07155187

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Sponsor: AbbVie

Knoxville, TN · Nashville, TN · +14 more sites

RecruitingPhase 1NCT06270706

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Sponsor: Pliant Therapeutics, Inc.

Nashville, TN · +15 more sites

RecruitingPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Daiichi Sankyo

Nashville, TN · +12 more sites

RecruitingPhase 1 / Phase 2NCT06362252

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Sponsor: Daiichi Sankyo

Nashville, TN · +25 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Nashville, TN · +36 more sites

RecruitingPhase 1NCT05877599

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Sponsor: AstraZeneca

Nashville, TN · +19 more sites

RecruitingPhase 1NCT07705035

DBC-664 in Adult Patients With Solid Tumors

Sponsor: Duboce Biopharmaceuticals, Inc.

Nashville, TN · +5 more sites

RecruitingPhase 1NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Sponsor: IDEAYA Biosciences

Nashville, TN · +22 more sites

RecruitingPhase 1NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Sponsor: AstraZeneca

Nashville, TN · +17 more sites

RecruitingPhase not listedNCT07124000

DESTINY-PANTUMOUR04

Sponsor: AstraZeneca

Nashville, TN · +17 more sites

RecruitingPhase 1 / Phase 2NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Sponsor: Neonc Technologies, Inc.

Nashville, TN · +7 more sites

RecruitingPhase 1NCT06858813

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Sponsor: AbbVie

Nashville, TN · +9 more sites

RecruitingPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sponsor: SystImmune Inc.

Nashville, TN · +21 more sites

RecruitingPhase 1 / Phase 2NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Sponsor: Blueprint Medicines Corporation

Nashville, TN · +9 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Nashville, TN · +95 more sites

RecruitingPhase 1NCT07217171

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Sponsor: EvolveImmune United, Inc

Nashville, TN · +14 more sites

RecruitingPhase 1 / Phase 2NCT07491497

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Sponsor: TRIANA Biomedicines, Inc.

Nashville, TN · +13 more sites

RecruitingPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Sponsor: Bristol-Myers Squibb

Nashville, TN · +24 more sites

RecruitingPhase 1 / Phase 2NCT06043817

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Sponsor: Pierre Fabre Medicament

Nashville, TN · +8 more sites

RecruitingPhase 1 / Phase 2NCT06567015

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Sponsor: Pierre Fabre Medicament

Nashville, TN · +1 more sites

RecruitingPhase 1NCT07027514

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Sponsor: Ankyra Therapeutics, Inc

Nashville, TN · +10 more sites

RecruitingPhase 1NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Sponsor: Eli Lilly and Company

Nashville, TN · +22 more sites

RecruitingPhase 1 / Phase 2NCT04683250

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Sponsor: Taiho Pharmaceutical Co., Ltd.

Nashville, TN · +8 more sites

RecruitingPhase 1 / Phase 2NCT04895709

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Sponsor: Bristol-Myers Squibb

Nashville, TN · +9 more sites

RecruitingPhase 1 / Phase 2NCT05592626

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Sponsor: Marengo Therapeutics, Inc.

Nashville, TN · +12 more sites

RecruitingPhase 1 / Phase 2NCT06706076

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Sponsor: BlossomHill Therapeutics

Nashville, TN · +23 more sites

RecruitingPhase 1NCT05433142

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Sponsor: Xencor, Inc.

Nashville, TN · +19 more sites

RecruitingPhase 1NCT06179160

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Sponsor: Incyte Corporation

Nashville, TN · +12 more sites

RecruitingPhase 1 / Phase 2NCT05098132

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Sponsor: Synthekine

Memphis, TN · Nashville, TN · +31 more sites

RecruitingPhase 3NCT06686771

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Sponsor: Canadian Cancer Trials Group

Nashville, TN · +70 more sites

RecruitingPhase 2NCT06695845

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Sponsor: Jazz Pharmaceuticals

Knoxville, TN · Nashville, TN · +15 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.